BOUCHERVILLE, Quebec, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Version française
Sandoz Canada Inc., a Novartis company, continues to innovate with the launch of PrAmiodarone Syringe (PrAmiodarone Hydrochloride for Injection), in a more convenient format for this important medicine which is used in heart rhythm disorders, often used in emergency situations.
PrAmiodarone Syringe in a 3 mL pre-filled syringe (50 mg/mL), is indicated for the initiation of treatment of documented, life-threatening, frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to all other treatment. PrAmiodarone Hydrochloride for Injection should be used for acute treatment until the patient's ventricular arrhythmias are stabilized.
Sandoz Canada plays a key role in providing medications in life-threatening situations for hospital emergency services, offering nearly 27 products in this area.
"The patient remains central to our decisions. This new pre-filled format meets the needs of health professionals because it will allow faster and safer use of this important medication by reducing handling and the risk of bacterial contamination," said Michel Robidoux, President of Sandoz Canada. "The introduction of this product demonstrates yet again that Sandoz Canada is a committed and trusted partner in the healthcare system. We are making every effort to meet the medical needs of patients while achieving the highest standards of quality, compliance and service, as well as supplying products at minimal cost".
PrAmiodarone Hydrochloride for Injection is also available in vial format manufactured by Sandoz Canada Inc.
For more information, please consult the Product Monograph available at www.sandoz.ca.
The foregoing release may contain forward-looking statements that can be identified by terminology such as "new" or similar expressions, or by express or implied discussions regarding future sales of the above-mentioned products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with the above-mentioned products to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the above-mentioned products will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. In particular, management's expectations regarding commercialization of the above-mentioned products could be affected by, among other things, additional analysis of clinical data in respect of the above-mentioned products, new clinical data, unexpected clinical trial results, unexpected regulatory actions or delays or government regulation generally, the company's ability to obtain or maintain patent or other proprietary intellectual property protection, competition in general, increased government, industry, and general public pricing pressures, and other risks and factors referred to in the Form 20-F filed by Novartis with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sandoz Canada Inc.
Established in Boucherville, Quebec, Sandoz Canada is part of Sandoz International GmbH, the world's second largest producer of generic drugs and a company of the Swiss multinational corporation, Novartis. A leader in its field, Sandoz Canada develops, produces, markets and distributes a wide range of generic products used, among others, in anesthesia, infectious diseases, oncology, cardiology, dermatology and pain management. The Boucherville manufacturing plant specializes in the production of key injectable products.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.coz_Global.
A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=35423
CONTACT: For further information, contact: Annick Lambert Executive Director Communications firstname.lastname@example.org 450-641-4903 ext. 2964
Source: Sandoz Canada